Showing 2,241 - 2,260 results of 110,318 for search '(( a point decrease ) OR ( 5 ((point decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.57s Refine Results
  1. 2241
  2. 2242
  3. 2243

    RelA–TA2 docks itself onto a series of interlinked hydrophobic grooves of TAZ1 through a number of hydrophobic residues, which serve as anchor points. by Sulakshana P. Mukherjee (453389)

    Published 2013
    “…<p>Disruption of any of the anchor points leads to the destabilization of the whole binding architecture of the complex. ∼2,800 Å<sup>2</sup> of RelA–TA2 surface area are buried upon formation of RelA–TA2:TAZ1 complex. …”
  4. 2244
  5. 2245
  6. 2246
  7. 2247
  8. 2248
  9. 2249
  10. 2250
  11. 2251

    IL-35 decreased the prevalence of Th17 in CD4+ T cells. by Yin Zongyi (3111660)

    Published 2017
    “…<p>(A)The ratio of Th17 in CD4+ T cells. (B) Representative diagram showing Th17’s ratio in CD4+ T cells was significantly decreased in the IL-35 group compared to that in the control group (0.3% vs. 7.2% on day 5, P<0.01). …”
  12. 2252
  13. 2253
  14. 2254
  15. 2255

    DataSheet5_Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening.ZIP by Sabrina R. Mackinnon (12496324)

    Published 2022
    “…<p>Primary hyperoxaluria type I (PH1) is caused by AGXT gene mutations that decrease the functional activity of alanine:glyoxylate aminotransferase. …”
  16. 2256
  17. 2257
  18. 2258

    Decreased s.c. growth of CNDT 2.5 cells after systemic administration of DOPC liposome-conjugated siNRP-2. by Shaija Samuel (341436)

    Published 2013
    “…NRP-2-siRNA DOPC-treatment led to a significant decrease in tumor growth compared with cntr siRNA DOPC-treatment (264.4 mm<sup>3</sup> vs. 751.3 mm<sup>3</sup>, respectively; *<i>p</i> = 0.01). …”
  19. 2259
  20. 2260

    LA decreases infarct size in rats subjected to I/R injury. by Chao Deng (329151)

    Published 2013
    “…<p>Representative illustrations of infarct size as stained by Evans Blue and TTC (a). LA decreased infarct size compared with I/R+V group and wortmannin pretreated group (b). …”